Cargando…

Phosphodiesterase 4-targeted treatments for autoimmune diseases

Advancements in phosphodiesterase (PDE)-targeted therapies have shown promise in recent years for treating patients with a variety of autoimmune diseases. This review summarizes the development of PDE4 inhibitors and the associated literature with a focus on treatments for autoimmune diseases. After...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Neal, Goldminz, Ari M, Kim, Noori, Gottlieb, Alice B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3616808/ https://www.ncbi.nlm.nih.gov/pubmed/23557064 http://dx.doi.org/10.1186/1741-7015-11-96

Ejemplares similares

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic, Milica, et al.
Publicado: (2021)

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Clinical Implication of Phosphodiesterase-4-Inhibition
por: Schick, Martin Alexander, et al.
Publicado: (2022)

Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases
por: Wittmann, Miriam, et al.
Publicado: (2013)

Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target
por: Motta, Nadia Alice Vieira, et al.
Publicado: (2021)

Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases
por: Nguyen, Hoang Oanh, et al.
Publicado: (2023)

To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?
por: Zheng, Yang, et al.
Publicado: (2023)

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement
por: Reneerkens, Olga A. H., et al.
Publicado: (2008)

Selective Phosphodiesterase 4B Inhibitors: A Review
por: Azam, Mohammed Afzal, et al.
Publicado: (2014)

Phosphodiesterase 4B: Master Regulator of Brain Signaling
por: Tibbo, Amy J., et al.
Publicado: (2020)

Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke
por: Wang, Haitao, et al.
Publicado: (2018)

Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer’s disease
por: Sheng, Jianwen, et al.
Publicado: (2022)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Editorial: Phosphodiesterases as Drug Targets in Airway and Inflammatory Diseases
por: Mokry, Juraj, et al.
Publicado: (2021)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
por: Zhang, Wen-Hao, et al.
Publicado: (2016)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
por: Giorgi, Mauro, et al.
Publicado: (2020)

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases
por: Kawamatawong, Theerasuk
Publicado: (2021)

Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review
por: Martin, Clémence, et al.
Publicado: (2021)

Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19
por: Dalamaga, Maria, et al.
Publicado: (2020)

Targeted Immunotherapy for Autoimmune Disease
por: Jung, Seung Min, et al.
Publicado: (2022)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

The impact of skin disfigurement in patients with autoimmune connective tissue disorders on quality of life, willingness-to-pay, and time trade-off: A cross-sectional analysis
por: Trepanowski, Nicole, et al.
Publicado: (2022)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
por: Moschos, Marilita M, et al.
Publicado: (2016)

Functional modulation of phosphodiesterase-6 by calcium in mouse rod photoreceptors
por: Turunen, Teemu, et al.
Publicado: (2021)

Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked DNA-adducts
por: Brettrager, Evan J., et al.
Publicado: (2019)

Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation
por: Li, Heng, et al.
Publicado: (2021)

Novel insights in phosphodiesterase 4 subtype inhibition to target neuroinflammation and stimulate remyelination
por: Schepers, Melissa, et al.
Publicado: (2023)

Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity
por: Zekeridou, Anastasia, et al.
Publicado: (2019)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Dual Activation of Phosphodiesterase 3 and 4 Regulates Basal Cardiac Pacemaker Function and Beyond
por: Vinogradova, Tatiana M., et al.
Publicado: (2021)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2015)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
por: Giannitsas, Konstantinos, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_v2e6fqvrckoe14qrgmbd2f7dam